1. Home
  2. PRTA vs EMX Comparison

PRTA vs EMX Comparison

Compare PRTA & EMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • EMX
  • Stock Information
  • Founded
  • PRTA 2012
  • EMX N/A
  • Country
  • PRTA Ireland
  • EMX Canada
  • Employees
  • PRTA N/A
  • EMX N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • EMX
  • Sector
  • PRTA Health Care
  • EMX
  • Exchange
  • PRTA Nasdaq
  • EMX Nasdaq
  • Market Cap
  • PRTA 472.1M
  • EMX 338.0M
  • IPO Year
  • PRTA N/A
  • EMX N/A
  • Fundamental
  • Price
  • PRTA $8.20
  • EMX $3.65
  • Analyst Decision
  • PRTA Buy
  • EMX Strong Buy
  • Analyst Count
  • PRTA 10
  • EMX 2
  • Target Price
  • PRTA $14.86
  • EMX $5.38
  • AVG Volume (30 Days)
  • PRTA 1.2M
  • EMX 447.8K
  • Earning Date
  • PRTA 08-04-2025
  • EMX 08-11-2025
  • Dividend Yield
  • PRTA N/A
  • EMX N/A
  • EPS Growth
  • PRTA N/A
  • EMX N/A
  • EPS
  • PRTA N/A
  • EMX 0.04
  • Revenue
  • PRTA $10,341,000.00
  • EMX $29,864,000.00
  • Revenue This Year
  • PRTA N/A
  • EMX $11.08
  • Revenue Next Year
  • PRTA $389.77
  • EMX $3.72
  • P/E Ratio
  • PRTA N/A
  • EMX $80.97
  • Revenue Growth
  • PRTA N/A
  • EMX N/A
  • 52 Week Low
  • PRTA $4.32
  • EMX $1.59
  • 52 Week High
  • PRTA $22.83
  • EMX $3.66
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 58.73
  • EMX 74.62
  • Support Level
  • PRTA $8.05
  • EMX $3.04
  • Resistance Level
  • PRTA $8.73
  • EMX $3.37
  • Average True Range (ATR)
  • PRTA 0.38
  • EMX 0.12
  • MACD
  • PRTA -0.05
  • EMX 0.03
  • Stochastic Oscillator
  • PRTA 47.62
  • EMX 97.58

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

About EMX EMX Royalty Corporation (Canada)

EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.

Share on Social Networks: